Global Tremfya market size and share is currently valued at USD 3.92 billion in 2024 and is anticipated to generate an estimated revenue of USD 7.99 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 7.4% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034
Market Growth Drivers
- Rising Prevalence of Psoriasis and Psoriatic Arthritis
Autoimmune diseases, particularly psoriasis and psoriatic arthritis, are increasing globally due to genetic predispositions, environmental factors, and changing lifestyles. According to health organizations, psoriasis affects approximately 2–3% of the global population. Tremfya’s mechanism of action, which selectively inhibits IL-23, makes it highly effective in reducing inflammation and managing symptoms in moderate-to-severe cases. This growing patient base continues to drive consistent demand. - Shift Toward Targeted Biologic Therapies
Traditional therapies such as corticosteroids and methotrexate often result in limited efficacy and side effects. Tremfya, as a next-generation biologic, offers a targeted approach with minimal systemic toxicity. The medical community’s increasing preference for biologics with precise mechanisms of action is accelerating Tremfya adoption in both developed and emerging healthcare systems. - Expanding Clinical Indications
Janssen’s ongoing research and development efforts are exploring Tremfya’s potential in treating Crohn’s disease, ulcerative colitis, and other inflammatory disorders. If successful, these trials could significantly broaden Tremfya’s therapeutic scope and market size. Such pipeline expansion provides a strategic opportunity for the company to diversify its revenue streams and strengthen its competitive position. - Improved Patient Adherence and Convenience
Tremfya’s subcutaneous administration once every eight weeks offers superior convenience compared to competing therapies requiring more frequent injections. Improved adherence directly translates into better treatment outcomes, reinforcing physician preference for Tremfya in long-term management. - Growing Healthcare Infrastructure and Reimbursement Support
Increasing healthcare investments in emerging economies, coupled with improved access to biologics through favorable reimbursement policies, are fostering market penetration. Governments and insurers are recognizing the long-term cost-effectiveness of biologic therapies like Tremfya, which reduce hospitalization and disease complications.
Key Trends Shaping the Market
- Personalized Medicine and Biomarker Development
The growing emphasis on personalized medicine is influencing biologic treatment strategies. Companies are investing in identifying biomarkers that predict patient response to Tremfya, improving clinical outcomes and reducing trial-and-error in therapy selection. - Digital Integration in Patient Monitoring
The use of digital health tools for patient monitoring and adherence tracking is becoming a norm. Tremfya’s integration with mobile health applications allows real-time patient engagement, ensuring timely administration and improved disease management outcomes. - Increased Competition in the IL-23 Inhibitor Space
The success of Tremfya has encouraged the entry of other IL-23 inhibitors such as Skyrizi (risankizumab) and Ilumya (tildrakizumab). While competition is intensifying, it also validates the therapeutic significance of IL-23 inhibition. Janssen’s strong clinical data and patient satisfaction rates continue to differentiate Tremfya from its peers. - Strategic Collaborations and Partnerships
Pharmaceutical collaborations for joint research, manufacturing, and distribution are becoming central to sustaining growth. Janssen’s partnerships with regional distributors and healthcare providers ensure Tremfya’s availability in more than 70 countries, expanding its global footprint. - Sustainability in Biologic Manufacturing
With growing environmental concerns, biologics manufacturers are adopting sustainable production processes. Janssen’s efforts toward eco-efficient manufacturing and reduced waste generation in Tremfya’s production align with global sustainability trends in the pharmaceutical sector.
Research Scope and Future Outlook
The research scope of the Tremfya market extends beyond dermatology and rheumatology into potential new indications and improved formulations. The ongoing clinical trials evaluating Tremfya for Crohn’s disease and ulcerative colitis may open new revenue opportunities in the gastrointestinal therapeutic segment. In addition, next-generation delivery systems, such as auto-injectors and prefilled pens, are enhancing patient comfort and safety, further supporting market expansion.
From a geographic perspective, North America currently leads the global Tremfya market, driven by advanced healthcare infrastructure, high biologics adoption rates, and extensive insurance coverage. Europe follows closely, supported by strong regulatory frameworks and growing patient awareness. Meanwhile, Asia-Pacific is anticipated to exhibit the highest growth rate during the forecast period, driven by expanding healthcare access, rising disposable incomes, and government initiatives to promote biologic treatments in countries such as China, India, and Japan.
The research and development landscape also involves continuous monitoring of long-term efficacy and safety data, real-world evidence studies, and head-to-head comparisons with other IL-23 inhibitors. The outcomes of these studies are expected to further validate Tremfya’s clinical superiority and enhance physician confidence in prescribing the drug.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/tremfya-market
Major Key Players:
- Johnson & Johnson
Market Segmentation
The Tremfya market can be segmented based on indication, distribution channel, dosage form, and region.
- By Indication:
- Plaque Psoriasis: This segment dominates the market, accounting for the largest share, as Tremfya is primarily indicated for moderate-to-severe plaque psoriasis.
- Psoriatic Arthritis: Increasing clinical adoption and positive outcomes in reducing joint pain and inflammation are driving this segment’s growth.
- Emerging Indications: Clinical trials for Crohn’s disease and ulcerative colitis are expected to create new growth avenues in the near future.
- By Distribution Channel:
- Hospital Pharmacies: Major share due to physician-prescribed administration and biologic management protocols.
- Retail Pharmacies: Growing accessibility and patient refills for long-term therapy support market growth.
- Online Pharmacies: Increasing acceptance of digital prescription fulfillment and patient convenience is boosting online sales, especially in developed markets.
- By Dosage Form:
- Prefilled Syringe: The most common format used in clinical and home-based settings due to ease of use and precision dosing.
- Auto-Injector: Expected to gain traction due to its simplicity and enhanced patient adherence.
- By Region:
- North America: The largest market, driven by high biologic therapy adoption and robust reimbursement systems.
- Europe: Significant market share due to increasing regulatory approvals and favorable healthcare policies.
- Asia-Pacific: Fastest-growing region owing to rising awareness, improved healthcare access, and expanding patient pool.
- Latin America & Middle East & Africa: Emerging markets offering potential growth through improved biologic distribution networks.
Conclusion
The global Tremfya market is poised for substantial growth, supported by strong clinical efficacy, expanding indications, and increasing acceptance of biologic therapies. As autoimmune and inflammatory diseases continue to rise, Tremfya’s targeted mechanism and long dosing intervals position it as a leading choice in advanced immunotherapy. The next decade will likely witness expanded therapeutic applications, digital integration in treatment adherence, and greater accessibility through global healthcare collaborations.
With continuous innovation, research, and strategic partnerships, Tremfya is not only transforming the treatment paradigm for autoimmune diseases but also reinforcing the growing potential of IL-23 inhibitors in modern medicine.
More Trending Latest Reports By Polaris Market Research:
Hospital Electronic Health Records Market
Healthcare Mobile Robots Market
Self Contained Breathing Apparatus Market